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The development of alternatives for autologous bone grafts is a major focus of
bone tissue engineering. To produce living bone-forming implants, skeletal stem and
progenitor cells (SSPCs) are envisioned as key ingredients. SSPCs can be obtained from
different tissues including bone marrow, adipose tissue, dental pulp, and periosteum.
Human periosteum-derived cells (hPDCs) exhibit progenitor cell characteristics and have
well-documented in vivo bone formation potency. Here, we have characterized and
compared hPDCs derived from tibia with craniofacial hPDCs, from maxilla and mandible,
respectively, each representing a potential source for cell-based tissue engineered
implants for craniofacial applications. Maxilla and mandible-derived hPDCs display
similar growth curves as tibial hPDCs, with equal trilineage differentiation potential
toward chondrogenic, osteogenic, and adipogenic cells. These craniofacial hPDCs are
positive for SSPC-markers CD73, CD164, and Podoplanin (PDPN), and negative for
CD146, hematopoietic and endothelial lineage markers. Bulk RNA-sequencing identified
genes that are differentially expressed between the three sources of hPDC. In particular,
differential expression was found for genes of the HOX and DLX family, for SOX9 and
genes involved in skeletal system development. The in vivo bone formation, 8 weeks
after ectopic implantation in nude mice, was observed in constructs seeded with tibial
and mandibular hPDCs. Taken together, we provide evidence that hPDCs show different
profiles and properties according to their anatomical origin, and that craniofacial hPDCs
are potential sources for cell-based bone tissue engineering strategies. The mandible-
derived hPDCs display - both in vitro and in vivo - chondrogenic and osteogenic
differentiation potential, which supports their future testing for use in craniofacial bone
regeneration applications.
Keywords: cell differentiation, mandible, maxilla, mesenchymal stromal cells, osteogenesis, periosteum,
tibia, transcriptome
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 November 2020 | Volume 8 | Article 554984
fcell-08-554984 November 19, 2020 Time: 16:38 # 2
Groeneveldt et al. Bone Tissue Engineering Using hPDCs
INTRODUCTION
The development of effective treatments for large bone defects
incurred by trauma, osteonecrosis or tumor resection remains
a challenge, which is further complicated by factors such as
infections and congenital abnormalities. Currently, autografts
are considered as the standard treatment of these bone defects,
however, this approach requires large volumes of bone. In
addition, it also requires a second surgical site where donor
tissue is harvested, thereby introducing donor site morbidity
(including pain) and potential major complications (in up to
10% of the cases; Arrington et al., 1996). These include vascular
injuries or deep infection in the donor site, and the possibility
of herniation of abdominal contents in case an iliac crest graft is
used. Furthermore, usually these donor sites provide insufficient
quantities of tissue for filling large bone defects and, in addition,
poor vascularization of the tissue graft can lead to necrosis
(Meijer et al., 2008).
Bone tissue engineering presents an opportunity for the
repair of large bone defects, with the engineered constructs
classically being composed of appropriate cells that are able
to proliferate and differentiate, and growth factors to instruct
cell differentiation in a 3D environment that provides some
biomechanical support (Leijten et al., 2015). Skeletal stem and
progenitor cells (SSPCs), often referred to as mesenchymal
stromal cells (MSCs), whereas these originate from various tissues
including bone marrow, adipose tissue, gingiva, dental pulp and
the periosteum, are being assessed for their potential in bone
tissue engineering. Recently, a bona fide human skeletal stem cell
characterized by a PDPN+ CD146− CD73+ CD164+ signature
was identified (Chan et al., 2018). This stem cell population
demonstrates significant amplification properties in response to
fracture. Similarly, periosteum-derived cells (PDCs) undergo a
rapid expansion to assist in callus formation (Colnot et al.,
2012), suggesting the presence of a stem or progenitor cell
population among PDCs.
Depending on their tissue of origin, differences in
the properties of SSPCs regarding cellular proliferation,
differentiation and senescence, as well as cytokine release
and gene/mRNA expression profiles have been documented
(Dominici et al., 2006; Kern et al., 2006; Tsai et al., 2007).
Although bone marrow-derived SSPCs (BM-SSPCs) are
osteogenic in vitro and form bone tissue in vivo, the bone
forming cells in a long bone fracture forming the callus are
predominantly PDCs (Colnot et al., 2012). Furthermore,
periosteum forms a larger callus with a higher mineral content
compared to bone marrow (Guichet et al., 1998), and cells in
the periosteum display higher proliferation following injury
(Brighton and Hunt, 1997). Ultimately, some data suggests
that PDCs contain a higher bone regenerative potential than
BM-SSPCs (Duchamp de Lageneste et al., 2018). For these
reasons PDCs are increasingly studied as a clinically relevant
source for bone tissue engineering purposes (Nakahara et al.,
1991; De Bari et al., 2006; van Gastel et al., 2012; Owston et al.,
2019; Bolander et al., 2020).
The anatomical location and other types (e.g., developmental
molecular signatures) of positional information are important
factors when studying in vivo bone formation (Leucht et al.,
2008). During development, facial cartilage and bone are
predominantly derived from cranial neural crest, unlike long
bones, such as the tibia, that originate from limb skeletal
precursors derived from the somatic layer of the lateral plate
mesoderm (Noden, 1982; Couly et al., 1993). In the neural
plate stage embryo, neural crest and placodal cells develop
in the future cranial region at the border of the neural plate
with the non-neural ectoderm under the influence of FGF
signaling together with precisely dosed Wnt and/or BMP
signaling. The actions of these signals converge on specific gene
families of Msh-type homeobox (MSX1, MSX2), distal-less
homeobox (DLX) and paired domain (PAX) transcription factors
(Villanueva et al., 2002; Tribulo et al., 2003; Meulemans and
Bronner-Fraser, 2004; Green et al., 2015). The cranial neural
crest cells extensively migrate to the pharyngeal arches and
form multiple ectomesenchymal cell types including thymus
cells, odontoblasts, osteoblastic, adipogenic and chondrogenic
cells, muscle cells and neuronal ganglia (Green et al., 2015).
Craniofacial bone tissue has a higher turnover rate, “ages”
more slowly, and has higher levels of osteoblastic markers
compared to appendicular skeletal bone tissue such as that
from tibia (Aghaloo et al., 2010). Furthermore, substantial
differences in structure and bone biology exist between maxillary
and mandibular bone tissue. Maxillary bone tissue arises
by intramembranous ossification and consists of trabecular
bone surrounded by a thin cortical layer, has low bone
density and mineral content, and is highly vascularized.
Mandibular bone tissue develops by both endochondral
ossification and intramembranous ossification. It consists of
lamellar bone tissue that is surrounded by a thick cortical
layer, has a high mineral content and bone density, and
shows more centralized vascularization (Park et al., 2008;
Lindhe et al., 2013). In a first step to assess the implications
of these differences on tissue regeneration strategies, Leucht
et al. (2008) performed cross-grafting of tibial periosteum
onto craniofacial defects and vice versa, and further have
shown that embryonic origin and homeobox gene expression
influenced the regeneration potential. Despite these well-
known differences in bone origin, structure and biology –
and their effect on tissue regeneration strategies – many bone
tissue engineering therapies intended for use in maxillofacial
context continue using the same cell source as their long
bone counterparts.
In this study, we built on the work of Leucht et al.
(2008), toward clinical translation. We investigate the molecular
differences of in vitro expanded periosteal cells from maxilla
and mandibula in the context of their potential use as
cell source for maxillofacial tissue engineering applications,
using tibial hPDCs as benchmark. Cell surface markers,
growth curves, trilineage differentiation potential, gene/mRNA
expression and in vivo bone formation were assessed. We
show that craniofacial PDCs meet essential criteria of SSPCs
(Chan et al., 2018). In addition, in vitro differentiation and
the mRNA profiling by bulk RNA-sequencing (RNA-seq)
show that hPDCs exhibit different properties depending on
their retrieval site.
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MATERIALS AND METHODS
Isolation and Culture of hPDCs
Periosteal samples (5× 10 mm) were obtained from the posterior
areas of the maxilla and mandible of 16- to 30-year-old healthy
patients who underwent bimaxillary orthognathic surgery,
after informed consent was obtained (Belgian registration
number B322201731127). The tibial samples were harvested by
orthopedic surgeons as described previously (Eyckmans and
Luyten, 2006). These samples were digested in medium consisting
of Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% Fetal Bovine Serum (FBS; Thermo Fisher Scientific,
Waltham, MA, United States) and 1% antibiotics-antimycotics
solution (100 units penicillin/ml, 100 µg streptomycin/ml and
0.25 µg amphotericin-B/ml; Invitrogen), from here on referred
to as DMEM-complete (DMEM-C), in addition of 4,400 units per
10 ml Collagenase type-IV (Gibco) under constant agitation for
16 h. Cells were from then on cultured in DMEM-C. Population
doublings (PD) of these human PDCs (hPDCs) were calculated
upon passaging using the formula log2(n2)−log2(n1), with n1
representing the number of cells seeded in the dish/flask and
n2 the number of cells obtained after trypsinization (TrypLE,
Thermo Fisher Scientific) of cells from the same dish/flask at
90% confluency.
Cellular Senescence
For detection of senescent cells, 105 cells were plated per well in
a 6-well plate in DMEM-C. After one day, the cells were fixed
using 4% paraformaldehyde (PFA) for 5 min, rinsed using PBS
and stained with 2 ml/well filtered (0.22 µm; Millex-GP) staining
solution consisting of 36 mM citric acid, pH 6.0 (Sigma Aldrich),
4.5 mM potassium ferricyanide (Merck), 0.14 M NaCl, 1.8 mM
MgCl2 (Merck) and 1 mg/ml X-gal (Biotium). After 6 h, the cells
were imaged using a Primovert inverted microscope (Zeiss).
Cell Proliferation
For detection of proliferating cells, staining for incorporated
EdU was performed using the Click-iTTM EdU Alexa FluorTM
555 Imaging Kit (Thermo Fisher Scientific) according to the
manufacturer’s protocol. In short, 105 cells/well were seeded
in a 6-well plate in DMEM-C. The following day, medium
was replaced with DMEM-C containing 10 µM EdU, followed
by an incubation of 72 h. Next, cells were fixated using 3,7%
formaldehyde in PBS (VWR) for 15 min, rinsed twice with 3%
bovine serum albumin (BSA, Sigma Aldrich) in PBS and lysed
with 0.5% Triton X-100 in PBS (Sigma Aldrich) for 20 min.
This was followed by adding the Click-iT reaction cocktail for
30 min in absence of light, quick washing steps of 1 min using
subsequently 3% BSA dissolved in PBS and later on in PBS,
addition of the Hoechst solution for 30 min in a 1:2,000 dilution
in PBS and final washing steps using PBS for 1 min.
Cell Metabolism
Cell metabolism was measured by using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Living cells
contain the mitochondrial reductase enzyme, which reduces
MTT toward formazan forming salt crystals. By measuring
the amount of reduction of MTT toward formazan, the
cell metabolism was measured. This was done by removing
remaining MTT and solubilizing of the salt crystals in order to
get with the different quantities of salt crystals corresponding
differences in color intensity (Mosmann, 1983). Tests were
performed as technical replicates 6 times per donor at 6, 9, and
12 weeks of culture. 10,000 cells were seeded in a 24-well plate
in 0.5 ml DMEM-C. After 1 day, DMEM-C was replaced with
DMEM containing 250 µg MTT/ml (Sigma Aldrich). After 4 h,
medium and remaining MTT were removed and 1 ml absolute
ethanol was added to each well in order to solubilize the salt
crystals. These solutions were transferred to a 96-well plate and
absorbance was read at 570 and 670 nm with a Synergy HT reader
(BioTek). In order to calculate the metabolic rate, the background
absorbance (at 670 nm) was subtracted from the absorbance at
570 nm and corrected for the blank values which were obtained
by performing all steps on wells containing no cells.
Flow Cytometry
106 cells were at passage 6 washed in 500 µl PBS + 1%
FBS and incubated at the following dilutions with anti-CD90-
APC (1:250), anti-CD164-PE (1:250), anti-CD45-FITC (1:1,000),
anti-CD31-FITC (1:1,000), anti-CD235ab-FITC (1:1,000; all
from BioLegend), anti-CD146-BV711 (1:250), anti-CD73-BV395
(1:250) and anti-PDPN-BV510 (1:100; all from BD Bioscience)
in 200 µl PBS + 1% FBS for 15 min in a dark area.
The cells were then washed twice with 1% FBS in PBS.
For compensation controls, UltraComp eBeads Compensation
Beads (Thermo Fisher Scientific) were used. Gating was
performed using Fluorescence-Minus-One (FMO) controls.
Fluorescence measurement was performed on a FACS Calibur
(BD Biosciences) using 100,000 events.
Differentiation of hPDCs
Human periosteum-derived cells were primed for adipogenic,
osteogenic and chondrogenic differentiation for 14, 21, and
7 days, respectively. Analysis was performed by staining with Oil
Red O, Alizarin Red and Alcian Blue, respectively.
For adipogenic differentiation of hPDCs, cells were cultured
in 24-well plates at a density of 19,000 cells/well in 0.5 ml
DMEM-C. After 2 days, the medium was changed for adipogenic
differentiation medium, i.e., Minimum Essential Medium
Eagle - alpha modification (α-MEM; Invitrogen supplemented
with 10% FBS, 1% antibiotics-antimycotics solution, 1 µM
dexamethasone + 10 µg/ml human insulin (Sigma Aldrich),
100 µM indomethacin (Sigma Aldrich) and 25 µM 3-isobutyl-
1-methylxanthine (Sigma Aldrich). The cells were cultured in a
humidified atmosphere at 5% CO2 and 37◦C for 14 days and
medium was replaced every 2 days. Lipid droplets were stained
by Oil Red O. Cells in monolayer were washed in PBS and fixed
for 30 min at room temperature in 10% formaldehyde (VWR)
diluted in PBS. Next, cells were washed with Milli-Q water and
rinsed in 60% isopropanol (VWR) diluted in Milli-Q water. Cells
were allowed to dry completely and then stained with 0.2% Oil
Red O (Sigma Aldrich) in Milli-Q water for 60 min. These cells
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were then washed with Milli-Q water before obtaining pictures
using the Primovert microscope (Zeiss).
For osteogenic differentiation of hPDCs, cells were cultured
in 24-well plates at a density of 8,550 cells per well in 0.5 ml
DMEM-C, first allowing them to proliferate. After 1 day, medium
was then changed for osteogenic medium consisting of DMEM-
C supplied with 100 nM dexamethasone (Sigma Aldrich), 10 mM
β-glycerophosphate disodium salt hydrate (Sigma Aldrich) and
50 µg/ml L-ascorbic acid 2-phosphate (Sigma Aldrich). Cells
were cultured in a humidified atmosphere at 5% CO2 and 37◦C
for 21 days, during which this medium was replaced every
3 days. Cells in monolayer were washed in PBS, fixed with
methanol at −20◦C (Fisher Scientific), stored for 1 h at 4◦C,
and washed again with PBS. Cells were stained for 1 h with a
2% Alizarin-S stain (Sigma Aldrich) in Milli-Q water with pH
adjusted to 4.2 (Merck) while the plate was placed on a shaker
for constant agitation. After staining, cells were washed with
Milli-Q water. Pictures were made using a Discovery.v8 SteREO
microscope (Zeiss).
For chondrogenic differentiation of hPDCs, the cells were
cultured in micromasses. Micromasses containing 200,000 cells
in 10 µl DMEM-C after centrifugation at 260 RCF for
10 min were added to individual wells of 24-well plates.
After 2 h, an extra 0.5 ml of DMEM-C was added to each
well. After 1 day, this medium was replaced by chondrogenic
inductive medium (DMEM-F12 (Invitrogen) containing 2% FBS,
antibiotics-antimycotics solution, 1x ITS + premix universal
culture supplement (Corning), 100 nM dexamethasone, 10 µM
Y27632 (Axon Medchem), 50 µg/ml L-ascorbic acid 2-
phosphate, 40 µg/ml proline (Sigma Aldrich) and 10 ng/ml
transforming growth factor-β1 (TGFβ1; PeproTech). These cells
were cultured under humidified conditions at 37◦C and 5%
CO2 for 7 days; medium was replaced every 2 days. Sulfated
glycosaminoglycans in the micromasses were stained by Alcian
Blue (Roth). The cells were rinsed with PBS and fixed with
excess ice-cold methanol for 1 h at 4◦C. This methanol was
removed and cells were rinsed with Milli-Q water prior to
adding 0.1% Alcian Blue staining solution (in 0.1 M HCl
at pH 2.4) for 1 h on a shaker. Alcian Blue stain was
removed and the cells were rinsed with Milli-Q water before
pictures were made using the Discovery.v8 SteREO microscope
(Zeiss). At days 1 (control), 3, 5 and 7, micromasses were
also obtained for confirmation of chondrogenic differentiation
by RT-qPCR. Micromasses were individually lysed in 350 µl
RLT buffer (Qiagen) containing 1% β-mercaptoethanol (Sigma
Aldrich) and homogenized by thoroughly pipetting up and down.
Samples were directly placed on ice and frozen at −80◦C until
further processing.
RNA Isolation, cDNA Synthesis and
Quantitative PCR
RNA was isolated from biological duplicates when a cumulative
PD∼10 was reached for RT-qPCR and at PD∼16 for RNA-seq
analysis. 106 cells were rinsed twice in PBS and centrifuged
at 260 RCF for 10 min. After removing the supernatant,
the cell pellet was lysed by adding 350 µl RLT buffer
(Qiagen) containing 1% β-mercaptoethanol (Sigma Aldrich) and
homogenized by thoroughly pipetting up and down. Samples
were directly placed on ice and frozen at −80◦C until further
processing. The Qiagen RNeasy mini kit was used to isolate
RNA according to the manufacturer’s instructions. cDNA was
obtained by reverse transcription of 500 ng of total RNA,
using the RevertAid H Minus First Strand cDNA Synthesis Kit,
1 mM oligo (dT)20 and random hexamer primers (Thermo
Fisher Scientific).
RT-qPCR was performed on expanded cells without
stimulation for differentiation for RNA encoding alkaline
phosphatase (ALPL), osteocalcin (BGLAP), osteopontin (SPP1),
peroxisome proliferator activated receptor gamma (PPARG),
collagen type-X (COL10A1), SRY (sex determining region
Y)-box 9 (SOX9) and vascular endothelial growth factor
receptor 1 (VEGFR-1). On chondrogenically differentiated
cells, the expression of aggrecan (ACAN), Col10A1 and Runt-
related transcription factor 2 (RUNX2) were defined. Samples
were processed and measured in technical duplicates on a
Step-One-Plus PCR machine (Applied Biosystems) using a
Sybr Green detection system (Life Technologies) according
to the manufacturer’s instructions, and normalized using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a
housekeeping gene. The respective primer sequences are listed in
the Supplementary Table S1.
RNA-Sequencing and Data Analysis
RNA-seq samples were obtained from three donors for the
maxillary samples (HP417, HP421, and HP424), four donors
for mandibular samples (HP418, HP422, HP425, and HP427),
and three tibial donors (HP415, HP420, and HP423). RNA-
seq samples were prepared from hPDCs at cumulative PD∼16
in technical duplicates (A and B) and cDNA libraries were
generated using the Illumina TruSeq Stranded mRNA Library
Prep Kit. These libraries were then sequenced (50 bp length)
according to the Illumina TruSeq Rapid v2 protocol in 5
runs, 2 lanes each run, on an Illumina HiSeq 2500 sequencer.
Low quality reads and contaminants (e.g., sequence adapters)
were removed using Trimmomatic (Bolger et al., 2014).
Sequences that passed the quality assessment were aligned
to the GRCh38 genome using HiSat2 (version 2.1.0) (Kim
et al., 2015). Transcript abundance level (transcript count)
was generated using HTSeq (version 0.9.1) (Anders et al.,
2015). The transcript counts were further processed using
R (version 3.4.0). Data normalization and removal of batch
effect was performed using the EDASeq R package (Risso
et al., 2011) and RUVseq package (Remove Unwanted Variation
from RNA-Seq package). Differential expression analysis was
performed using the edgeR R package (Robinson et al.,
2010), using the negative binomial generalized linear model
approach. Differentially expressed genes with false discovery
rate (FDR) ≤ 0.05 after Benjamini-Hochberg correction for
multiple testing and expression level greater than 1 count per
million (CPM) were retained and used for further processing,
gene ontology and pathway analysis. Gene enrichment analysis
was performed using metascape (Zhou et al., 2019). The RNA
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sequencing data is deposited at NCBI with GEO accession
number GSE149167.
In vivo Bone Formation
After proliferation, 106 cells suspended in 25 µl of DMEM-
C were seeded on NuOss scaffolds (21 mm3; ACEuropa). One
hour after seeding, an additional 5 ml of DMEM-C was added.
After overnight incubation at 37◦C and 5% CO2, scaffolds
were randomly implanted subcutaneously over the available
mice in triplicates with a maximum of 4 for each mouse at
the shoulder and the back in the limb region of 8-week-old
female NMRInu/nu mice (Janvier). All animal procedures were
approved by the local ethical committee for Animal Research (KU
Leuven). The animals were housed according to the guidelines
of the Animal Facilities at Leuven (KU Leuven). Explants were
harvested after 8 weeks.
Bone formation was analyzed using the Phoenix NanoTom
S CT system (GE measurement) at a voltage of 60 kV and a
current of 200 mA. An aluminium filter of 1 mm was used to
filter out the low energetic radiation. CTAn and Batch Manager
Software programs (Bruker micro-CT, Kontich, Belgium) were
used for 3-D quantification of the bone volume and calcium
phosphate (CaP) grains of the NuOss scaffold. A three-level
automatic Otsu segmentation algorithm was used to segment the
newly formed bone tissue and CaP-grains from the background
in combination with manually chosen thresholds. Noise was
reduced by removing black and white speckles smaller than
200 voxels and a closing operation of 2 voxels was performed
to solidify the resulting structure, providing binarized images
suitable for the 3-D analysis. Percentage of bone was calculated
with respect to total explant volume (Kerckhofs et al., 2013). After
decalcification in EDTA, dehydration through a series of graded
ethanol baths, embedding in paraffin and sectioning, histological
stainings were performed. Staining with hematoxylin and eosin
(H&E) was done by a dip in Hematoxylin-solution for 2 min,
followed by a wash in H2O and subsequently a staining in 1%
Eosin (Klinipath, Duiven, Netherlands) for 7 min (Bolander et al.,
2016). For Alcian Blue staining, samples were rehydrated, stained
for 30 min in 0.5% Alcian Blue (Roth) solution in 1 M HCl
(pH = 1). Nuclear Fast Red (Vector) was used for staining of
the nuclei during 5 min. For staining with Safranin O, samples
were dipped in acidic alcohol (1% HCl in 70% ethanol). Next,
they were placed in Fast Green (Klinipath) for 3 min, dipped
in 1% acetic acid and then stained in 0.1% Safranin O (Sigma
Aldrich) for 10 min. Masson’s trichrome staining was performed
using Bouin’s solution (Sigma Aldrich) as mordant followed by
5-minute-dips in Weigert’s Iron Hematocxylin Solution, Biebrich
Scarlet-Acid Fuchsin, Phosphotungstic/Phosphomolybdic Acid
Solution and Aniline Blue Solution (all from Sigma Aldrich),
followed by a dip in 1% acetic acid for 2 min. The sections
were cleared in HistoClear (National-Diagnostics) and mounted
in Pertex (Histolab). Pictures were made using the IX83
microscope (Olympus).
Statistical Analysis
Statistical analysis for cellular senescence, quantitative PCR and
in vivo bone formation was performed using the Kruskal-Wallis
test. In case p < 0.05 for Kruskal-Wallis, a two-sided
Wilcoxon test was performed to make comparisons for the
qPCR validation of the RNA-seq data and to analyze cellular
senescence, proliferation and metabolism rate. Student’s t-test
was used to make comparisons for the chondrogenically
differentiated micromasses. The Bonferroni correction was
used to correct for multiple testing. All statistical analyses
were performed in R (version 3.6.0). Results were considered
statistically significant at p < 0.05. Data are presented as mean
values ± standard deviation (SD) or 95% confidence interval
(CI) when stated.
RESULTS
Characterization of the Isolated and
Expanded Human Periosteum-Derived
Cells
Flow cytometric analysis was performed on culture expanded
hPDCs to confirm the presence of SSPCs (Figures 1A–I).
88.9% of the maxillary hPDCs were positive (+) for CD73,
CD164 and PDPN, while negative for CD31, CD45, CD235ab,
and CD146 (Figure 1J). In contrast, 87.7% of the mandibular
cells and 62.0% of the tibial hPDCs met the SSPC criteria.
All cells were selected based on their capacity to adhere to
plastic (Figures 1K–M).
Alcian Blue-positive micromasses from maxillary and
mandibular and tibial hPDCs indicated their ability to
differentiate toward the chondrogenic lineage (Figures 2A–C;
controls in Figures 2D–F). Adipogenic differentiation of
hPDC cultures in monolayer was verified by staining with Oil
Red O, for hPDCs obtained from the three different origins
(Figures 2G–I; controls in Figures 2J–L). Calcium phosphate
formed by osteogenic primed cells in monolayer was stained by
Alizarin Red (Figures 2M–O; controls in Figures 2P–R) and
showed mineral deposition by the hPDCs, independent of their
origin. Additional RT-qPCR on chondrogenically differentiated
micromasses at days 1 (control), 3, 5, and 7 showed that RUNX2
(Figure 2U) and COL10A1 (Figure 2T) were expressed at
higher levels after chondrogenic differentiation in comparison
to undifferentiated micromasses at day 1. Also ACAN was
expressed from day 5 at statistically significantly higher levels
compared to the controls (Figure 2S). These results indicated
that plastic-adherent hPDCs derived from maxilla and mandible
could be expanded, and that these cultured hPDCs were positive
for acknowledged SSPC surface markers and able to differentiate
toward three different cell types.
Human PDCs Can Be Expanded for
2 Months
We have tested the ability to expand hPDCs obtained from
maxilla versus mandible and tibia. The proliferation rates of
hPDCs during in vitro expansion under the culture conditions
used, measured in cumulative population doublings (CPDs),
were similar and independent of their origin (Figures 3A,B).
After 6, 9 and 12 weeks of expansion, staining with X-gal for
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FIGURE 1 | (A) Flow-cytometric analysis of periosteal-derived cells obtained from maxilla (A–C), mandible (D–F) and tibia (G–I). Gating is performed using FMO’s for
each run. n = 3. 100.000 events were read for each sample. (J) Summary of flow-cytometric analysis, n = 3 for each origin. SA-β-gal staining on periosteal cells
derived from maxilla (K), mandible (L), and tibia (M) demonstrating no precipitation of X-gal.
senescence-associated β-Galactosidase was performed. During
the first 9 weeks the average rates of such cells remained below
5%. After 12 weeks significantly higher rates were found, up
until 28% of the cells (p = 0.045; Figure 3C). Quantification
of proliferation was measured by staining for incorporated
EdU, again after expansion for 6, 9 and 12 weeks. About 75%
of the cells were EdU + after 6 and 9 weeks of expansion
(Figure 3D) with a significantly higher proliferation rate for
maxillary hPDCs after 6 weeks in comparison to mandibular
and tibial hPDCs.
Assessing cellular metabolic activity using the MTT
colorimetric assay, we saw a trend toward lower mitochondrial
metabolic rates in tibia-derived hPDCs, however, no
statistically significant differences were found between the
maxillary, mandibular and tibia-derived hPDCs (Figure 3E).
Furthermore, no decline in the metabolic activity was
observed after 12 weeks. From this, we conclude that
hPDCs, regardless of their tissue source, can be expanded
during at least 9 weeks, with an expected yield of about
350 million cells after 50 days of proliferation. This yield is
sufficient for typical applications in bone tissue engineering
(Lammens et al., 2020).
In vitro Analysis of Marker Genes on
Expanded hPDCs From 3 Different
Origins
In order to investigate further the differences in mRNA profiles
between the respective in vitro expanded hPDCs, we performed
RT-qPCR on acknowledged marker genes for bone. These include
ALP, a marker of osteogenic differentiation; BGLAP, coding
for a protein secreted in bone solely by osteoblasts; and SPP1,
a gene expressed by multiple cell types including osteoblasts
and osteoclasts. The steady-state transcripts of ALP are higher
in maxillary compared to mandibular (p = 0.025) and tibial
hPDCs (p = 0.0013) (Figure 4A), whereas BGLAP transcripts
showed no statistically significant differences (Figure 4B).
SPP1 was upregulated for tibia-derived cells when compared
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FIGURE 2 | Alcian Blue staining of chondrogenically differentiated hPDCs obtained from maxilla, mandible and tibia (A–C) and cells cultured in DMEM-C (D–F). Oil
Red O staining of adipogenically differentiated hPDCs (G–I) and cells cultured in DMEM-C as controls (J–L). Cells stained with Alizarin Red staining to detect calcium
phosphate deposition of osteogenically differentiated hPDCs (M–O) and controls cultured in DMEM-C (P–R). RT-qPCR performed at days 1 (control), 3, 5 and 7 for
the chondrogenic genes RUNX2, COL10A1 and ACAN showed as fold-change compared to the control after correction for GAPDH, n = 3 in biological triplicates.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 (S–U).
to hPDCs from mandible (p = 0.014; Figure 4C). For the
adipogenic receptor PPARG no differences were seen that are
statistically significant (Figure 4D). SOX9 was upregulated in
both maxillary and mandibular cells compared to tibial hPDCs
(p = 0.03 and p = 0.008, respectively; Figure 4E). VEGFR-
1 transcripts were higher in maxillary compared to tibial
(p = 0.007) and mandibular hPDCs (p = 0.04) (Figure 4F). Also
for COL10A1 an upregulation was seen for maxillary hPDCS
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FIGURE 3 | (A) Proliferation curves of hPDCs obtained from maxilla, mandible and tibia, wherein the X-bar displays the time in days and the vertical axis the
cumulative population doublings (CPD). (B) Mean proliferation curves of hPDCs from maxilla (red), mandible (green) and tibia (blue), with confidence interval showed
in gray. (C) Percentage of SA-β-gal staining-positive cells at 6, 9 and 12 weeks of expansion in DMEM-C. (D) Proliferation-capacity of hPDCs showed by the
percentage of EdU-positive cells after 6, 9, and 12 weeks of expansion in DMEM-C. (E) Metabolic activity shown by MTT-test of hPDCs obtained from maxilla (Mx),
mandible (Md) and tibia (T) after 6, 9 and 12 weeks of expansion in DMEM-C. *p ≤ 0.05, **p ≤ 0.01.
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FIGURE 4 | Expression level of ALPL (A), BGLAP (B), SPP1 (C), PPARG (D), SOX9 (E) VEGFR-1 (F) and COL10A1 (G) of hPDCs from maxilla (Mx), mandible (Md)
and tibia (T) after expansion in DMEM-C at PD = 10, n = 3 in biological duplicates for each origin corrected for GAPDH. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001.
compared to mandibular and tibial hPDCs (p = 0.016 and 0.013,
respectively, Figure 4G).
Bulk RNA-Seq of Cultured Adult hPDCs
Reveals Differences That Reflect
Different Embryonic Origins
We have also performed bulk RNA-seq on expanded cells.
Principal component analysis (PCA; Figure 5A) and the
hierarchical clustering (dendrogram in Figure 5B) show that
the differences in anatomical origin of the hPDCs are
reflected in bulk mRNA expression differences. To capture the
genes that contribute to this distinction, we have performed
differential gene expression analysis between the hPDCs. 780
differentially expressed genes (DEGs; FDR < 0.05, log fold
change > 1) were identified between tibial and maxillary
hPDCs. 291 of these were down-regulated and 489 up-
regulated in maxilla-derived hPDCs. Between mandible and
tibia-derived hPDCs 841 DEGs were identified, with 361 genes
down- and 480 genes up-regulated in mandibular hPDCs
(Figure 5C and Supplementary Tables S2, S3). In these
comparisons only around 33% of the DEGs are common
between maxilla and mandible derived hPDCs compared to
tibial hPDCs, attesting to the large difference that exists between
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FIGURE 5 | (A) Principal component analysis of RNA-sequencing on hPDCs obtained from maxilla (red), mandible (green) and tibia (blue). Each dot represents the
sample mean from a single donor. (B) Cluster dendrogram based on RNA-sequencing results. (C) Table showing the number of differentially expressed genes and
venn diagrams of differentially expressed genes between maxillary, mandibular and tibial hPDCs based on RNA-seq. (D) Heatmap of Hox and DLX family genes
based on RNA-seq data. (E) Heatmap of the 30 most differentially expressed genes in the comparisons maxilla (Mx) vs. tibia (T), mandible (Md) vs. T and Mx vs. Md.
maxilla and mandible-derived hPDCs. Finally, the comparison
between mandibular and maxilla-derived hPDCs identified 438
DEGs; 236 of these genes were up-, and 202 genes were
down-regulated in maxilla-derived hPDCs (Figure 5C and
Supplementary Table S4).
Next, we performed gene enrichment analysis on the DEGs
to capture the biological processes and molecular functions
that show significant changes. Genes that show up- and down-
regulation in both maxillary and mandibular hPDCs, compared
to tibial hPDCs, are involved in skeletal system development,
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extracellular structure organization, vascular development and
related pathways (Supplementary Figures S1, S2). Upregulated
genes in tibia showed more significant enrichment in bone
development related pathways (Supplementary Figures S1,
S2). In the comparison between maxillary and mandibular
hPDCs, genes that are up-regulated in mandibular (and also
down-regulated in maxillary) were enriched for terms related
to skeletal system development, bone remodeling, ossification
(Supplementary Figure S3). This reflects the chondrogenic
and osteogenic differentiation potential of mandible-derived
hPDCs compared to maxillary hPDCs. Down-regulated genes
in mandibular (and also up-regulated in maxillary) were
involved for terms that are not related to bone development
(Supplementary Figure S3).
The list of DEGs also pointed to differences among HOX-
and DLX-family genes between craniofacial and tibial hPDCs.
The majority of the HOX-family genes showed upregulation in
tibial hPDCs. However, some HOX genes (HOXC8, HOXD8,
HOXC9, HOXD9, and HOXA10) showed also higher expression
in craniofacial hPDCs (Figure 5D). From the DLX family, DLX1
was highly expressed in craniofacial and tibial hPDCs, and DLX5
in mandibular hPDCs.
The RNA-seq data were validated by RT-qPCR by taking
the top-10 DEGs in the 3 comparisons (Figure 5E and
Supplementary Table S5). Expression of HOXA11, encoding a
transcription factor regulating positional cell identity along the
anterior-posterior (AP) axis of embryonic segments (Liatsikos
et al., 2010; Raines et al., 2015), was elevated in tibial compared
to maxillary and mandibular hPDCs (p = 0.007 for both;
Figure 6A). Also, significantly higher expression values of
HOXA7, HOXA10, HOXC10, and the HOX transcript antisense
RNA (HOTAIR) were obtained for tibial hPDCs compared to
those from the craniofacial area, which confirmed the RNA-seq
results (Figures 6B–E). We conclude that tibia-derived periosteal
cells isolated from patients still express genes that are involved in
AP patterning in the embryo. DLX1, encoding a transcriptional
regulator and a downstream target of multiple transforming
growth factor beta (TGF-β) family members (Mimura et al.,
2016), was more highly expressed in mandibular compared to
tibial hPDCs (p = 0.007; Figure 6F). DLX5 is an early-BMP
responsive gene and encodes a transcription factor involved in
osteoblast differentiation (Li et al., 2008). This gene was more
strongly expressed by mandibular compared to tibial hPDCs
(p = 0.013; Figure 6G). DLX6, often proposed as paralog of
DLX1 (Li et al., 2008), did not show any statistically significant
difference (Figure 6H), but the antisense RNA encoded by DLX6
(DLX6-AS1), was down-regulated in mandibular compared
to tibial hPDCs (p = 0.007; Figure 6I). The latter is in
accordance with the trend toward a higher expression of DLX6
in mandibular hPDCs.
BARX1 is expressed during tooth development and neural
crest-derived craniofacial mesenchymal tissues, but is also known
for its inhibiting interaction on canonical Wnt signaling (Woo
et al., 2011; Lin et al., 2019). Expression of BARX1 was
higher in mandibular compared to tibial hPDCs (p = 0.007;
Figure 6J). LHX8 encodes a transcription factor that plays a
role in the development of the palate, in oogenesis and neuronal
differentiation (Choi et al., 2008; Flandin et al., 2011; Cesario
et al., 2015). However, LHX8 is also known to stimulate the
proliferation of MSCs, while a drop in LHX8 expression level
combined with increased levels of BMP2 promotes osteogenesis
(Wang et al., 2019). For LHX8 higher expression was found in
maxillary compared to tibial hPDCs (p = 0.013; Figure 6K).
PAX1, a target of Shh signaling that plays a role in axial
skeletogenesis (Wallin et al., 1994), showed a trend toward down-
regulation in hPDCs originating from the mandible, compared
to those from tibia (Figure 6L). PAX1 also positively regulates
the chondrogenic marker genes SOX5, ACAN, COL2A1, and
WW domain-containing protein 2 (WWP2) (Takimoto et al.,
2019). COL13A1 encodes the alpha-chain of one of the non-
fibrillar collagens and has previously been implicated in bone
mass and bone formation rate (Ylönen et al., 2005), but did not
show any statistically significant differences (Figure 6M). DPP4
plays an important role in glucose metabolism. Administration
of inhibitors against DPP4 results in an increase in bone mass by
upregulation of IL-10 expression and subsequent stimulation of
chondrocyte hypertrophy (Jung et al., 2013; Wang et al., 2018).
DPP4 was expressed less by maxillary compared to mandibular
hPDCs (p = 0.015; Figure 6N). GPC3, an antagonist of DPP4 and
involved in limb patterning and skeletal development via BMP4
(Paine-Saunders et al., 2000), did not show statistically significant
differences, but an opposing trend to DPP4 (Figure 6P). No
statistically significant differences were found for the G-protein
coupled receptor GPRC5C (Figure 6O). VEGFB, involved in
angiogenesis and endothelial cell physiology (Hagberg et al.,
2010), showed an upregulated trend in maxillary compared
to tibial and mandibular hPDCs (Figure 6Q). In total, we
could confirm, using RT-qPCR and after Bonferroni-correction,
statistically significant differences in expression for 11 out of the
30 DEGs selected from the RNA-seq lists.
In vivo Bone Formation
We assessed whether after 8-weeks bone formation in scaffolds
seeded with tibial hPDCs did occur; for this, we used Nano-
CT analysis of ectopically implanted scaffolds (Figures 7A,B).
No in vivo mineralized tissue was detected with maxilla-derived
hPDCs, whereas it was present, as a positive control, in constructs
seeded with tibial hPDCs (p = 0.04326) at an average of
0.0736 mm3 bone tissue (Figures 7A,B). Importantly, bone
formation by mandibular hPDCs was detected in 6 out of the
12 retrieved constructs, averaging 0.06 mm3 bone tissue in those
12 constructs. Staining with hematoxylin/eosin (HE) confirmed
that the mineralized tissue seen on CT-scans was indeed bone
tissue (Figures 7C–E). Staining of cartilage with Alcian Blue
showed more staining in scaffolds seeded with mandibular
hPDCs (Figures F–H). Staining for bone tissue with Masson’s
Trichrome confirmed the results obtained from both HE and
Alcian Blue staining (Figures I–K).
DISCUSSION
Research toward cell-based bone tissue-engineering recently
focused strongly on the properties of SSPCs and proposed
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FIGURE 6 | (A–Q) Expression level of genes found in top 10 from RNA-sequencing for each comparison, forming in total a top 30 list, confirmed on maxillary (Mx),
mandibular (Md) and tibial (T) hPDCs obtained from different donors at PD = 10, n = 3 in biological duplicates for each origin corrected for GAPDH. *p ≤ 0.05,
**p ≤ 0.01.
hPDCs as candidate cells (Roberts et al., 2015; Bolander et al.,
2020). We have documented the differences between PDCs
obtained from different anatomical locations (maxilla, mandible
and tibia, respectively) in vitro and also in vivo. FACS on
in vitro expanded cells scored them as CD73+, CD164+, and
PDPN+, each marker associated with SSPC identity, whereas
they were negative for hematopoietic lineage markers. The latter
is important, for the presence of one or more hematopoietic
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FIGURE 7 | Nano-CT imaging of scaffolds seeded with hPDCs obtained after 8 weeks of ectopic implantation with scaffold grains in light gray (white arrow) and
mineralized tissue in dark gray (white dashed arrow). (A) Volumetric percentage of mineralized tissue in each cell construct. (B) Histological imaging of those cell
constructs stained with Hematoxylin & Eosin (C–E), Alcian Blue (F–H) with bony tissue pointed by black arrows and Masson’s Trichrome (I–K).
markers on SSPCs was shown by others to underlie further
cellular differentiation accompanied by loss of stem cell state
(van Lochem et al., 2004). We concluded that 88% of our
in vitro expanded craniofacial cells fulfilled the applied SSPC
criteria, and 62% of our in vitro expanded tibial hPDCs, but
also acknowledged the limited relevance of these markers for
stem cell function (Ambrosi et al., 2019). Our hPDCs were able
to proliferate in vitro at comparable rates to each other, they
did not display senescence during 9 weeks of culture, and were
able to differentiate at CPD∼8 to osteogenic, chondrogenic
and adipogenic lineages. ALPL and BGLAP displayed higher
mRNA expression in vitro cultured hPDCs obtained from maxilla
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compared to tibia, which could underlie the higher in vitro
osteogenic potential of maxilla-derived hPDCs. For in vivo
endochondral bone formation, the mandibular hPDCs showed
a higher potential, possibly due to higher SOX9 expression
by these cells in vitro, again compared to tibial hPDCs. The
steady-state mRNA levels of VEGFR-1, encoding a receptor that
is normally upregulated during vascularization in healing of
fractured bones, were highest in maxillary hPDCs compared to
the other ones. This can be of interest when scaling-up tissue
engineering constructs that have diffusion limits of oxygen and
nutrients, since cell death or apoptosis in the center of the implant
has been reported if good vascularization is not achieved quickly
(Potier et al., 2007; Giannoni et al., 2010).
RNA-seq and further validation by RT-qPCR on separate
in vitro cultured samples thus reveal notable differences in gene
expression between hPDCs obtained from the three sites. These
are represented mostly by the higher expression of HOX and
DLX family genes steering skeletal system and other connective
tissue development, but also co-determine extracellular matrix
organization, collagen formation, and responses to growth
factors. Overall, these sets of genes are irrefutably relevant to
in vivo bone regeneration and form a solid basis for future
experiments that aim at improving bone tissue engineering
applications. HOXA7, HOXA10, HOXC10, and HOTAIR were
each upregulated in tibial hPDCs compared to those from the
craniofacial area. Hence, tibia-derived periosteal cells isolated
from adult patients still express genes that are involved in several
other processes, including anterior-posterior patterning in the
embryo, or these genes also have additional functions in cell
differentiation. Leucht et al. (2008) grafted periosteum from
the tibia onto craniofacial bone defects (and vice versa) and
demonstrated that HOXA11+ cells maintain their HOX status
after changing the environment, but HOXA11-negative cells
can start to express HOXA11 after changing the environment.
In this study, the change of environment, which in vitro
expansion is, could explain the presence of low expression of
HOX genes by hPDCs obtained from the maxilla and mandible.
DLX1 was expressed at a higher level in maxilla-derived
hPDCs. This could explain the higher osteogenic potential of
these cells in vitro. DLX5 acts as an early BMP-responsive
transcriptional activator driving osteoblastic differentiation of
cells, while DLX6 has been proposed as paralog of DLX1
(Li et al., 2008). These results suggest favoring the use of
mandibular hPDCs in craniofacial applications, since DLX5
and DLX6 where both up-regulated in these cells. However,
PAX1, a target of Shh signaling, but also positively regulating
the chondrogenic effector or marker genes SOX5, ACAN,
COL2A1, and WWP2 (Wallin et al., 1994; Takimoto et al.,
2019), was expressed at higher levels in tibial hPDCs. Taken
together, hPDCs obtained from maxilla, mandible and tibia
showed different gene/mRNA expression profiles, including
of relevant effector or marker genes, which could lead to
different direct or endochondral bone forming properties. This
could be exploited in bone tissue engineering strategies for
various anatomical locations. For a number of selected genes,
based on RNA-seq, we also could not reproduce the results
by RT-qPCR. We hypothesize that this is due to our use of
different donors throughout these comparisons, which made the
validation more stringent.
Analysis of hPDC-seeded scaffolds showed bone formation
8 weeks after ectopic implantation when seeded with tibial
and mandibular cells, but unexpectedly not with maxilla-
derived hPDCs. For the latter, cells show in vitro upregulation
of osteogenic genes compared to tibia-derived cells. We
hypothesize that maxilla-derived periosteal cells are less prone for
endochondral bone formation when the cells are not stimulated
by growth factors. Also local environmental cues influence the
ability of these cells to form bone, as demonstrated previously
through periosteal grafting experiments (Leucht et al., 2008). In
addition, the choice of the carrier or any coincidence in view
of the generally observed biological variability of the in vivo
ectopic bone formation assays, could account for the documented
difference (Ji et al., 2018).
To our knowledge, in vivo results of ectopic bone formation
using in vitro expanded maxilla-derived periosteal cells have not
been reported yet. Additional work is needed to investigate if
priming of hPDCs prior to implantation could be optimized
for craniofacial-derived hPDCs, as was shown for tibial hPDCs
(Bolander et al., 2016). The effects of priming tibia-derived
periosteal cells with different concentrations of calcium in
the medium on their bone-forming capacities in vivo, and
when using calcium phosphate scaffolds, have been documented
previously (Chai et al., 2012). Mandibular periosteal cells,
obtained from the region near the wisdom tooth, yield more
bone tissue in vivo when co-cultured with CD34+ endothelial
progenitors obtained from the umbilical cord, while a trend
toward a better osteogenic potential of mandibular periosteum-
derived cells cultured using cyclic tension force has also been
reported (Lee et al., 2014, 2017). For tibia-derived periosteal
cells, the effects of different calcium phosphate scaffolds on
in vivo bone formation capacities of such cells was also reported
(Kerckhofs et al., 2016). Others have stated the importance of
the combination of mesenchymal lineage-derived cells with type
of scaffold (Mattioli-Belmonte et al., 2015), but this has not
yet been explored with maxilla and/or mandible-derived cells.
Furthermore, many features of scaffolds contribute to the in vivo
outcome, including bio-compatibility, porosity, pore size, surface
properties, osteo-inductivity and mechanical properties (Salgado
et al., 2004). In addition, the predictability and robustness of
the in vivo formed bone construct as well as possible differences
in the speed of bone formation, and bone formation in an
orthotopic environment altogether, should also be evaluated
and/or improved in order to prepare translation toward the clinic
(Geris and Papantoniou, 2019).
We hypothesized that location and tissue of origin are
relevant for successful bone repair when using in vitro expanded
cell-based tissue engineering constructs. hPDCs from different
anatomical locations may be interesting sources, but would
display different properties and possibly differences in outcome
with regard to bone healing in vivo. Therefore, we focused
on documenting (dis)similarities between in vitro expanded
periosteum-derived cells from tibia, maxilla and mandible.
Progenitor cells from different anatomical sources indeed differ
in their transcriptomic signature and in vivo differentiation
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potential (Sacchetti et al., 2016). We have shown that in vitro
expanded hPDCs obtained from these respective sites do
not differ in their capacities to proliferate in vitro under
the experimental conditions used. However, the cells showed
differences in gene expression profiles and in vivo bone
formation. So, different properties, including embryonic origin
and (epi)genetic priming laid down within functionally similar
cell types, located at different anatomical sites, can be retained
during ex vivo expansion. This then influences the functional
outcome, here demonstrated by different skeletogenic potential of
SSPCs. It remains to be investigated if these observed differences
are critical for clinical outcomes, including remodeling of tissue
over time, and for which indications.
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